



SEQUENCE LISTING

<110> MAZAR, Andrew P.
JONES, Terence R.

<120> DIAGNOSTIC PROBES AND THERAPEUTICS TARGETING uPA AND uPAR

<130> 38369-169219

<140> US 09/670,537

<141> 2000-09-27

<150> US 60/157,012

<151> 1999-10-01

<160> 2

<170> PatentIn version 3.0

<210> 1

<211> 44

<212> PRT

<213> Homo sapiens

<400> 1

Ser	Asn	Glu	Leu	His	Gln	Val	Pro	Ser	Asn	Cys	Asp	Cys	Leu	Asn	Gly
1				5					10					15	

Gly	Thr	Cys	Val	Ser	Asn	Lys	Tyr	Phe	Ser	Asn	Ile	His	Trp	Cys	Asn
			20					25					30		

Cys	Pro	Lys	Lys	Phe	Gly	Gly	Gln	His	Cys	Glu	Ile
		35					40				

<210> 2

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<221> misc_feature

<222> ()..()

<223> uPA active site-targeting compound

<220>

<221> misc_feature

<222> (1)..(1)

<223> Xaa can be any amino acid

<220>

<221> misc_feature

<222> (2)..(2)

<223> Xaa can be any amino acid

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa can be any amino acid

<220>

<221> misc_feature

<222> (4)..(4)

<223> Xaa can be any amino acid

<220>

<221> misc_feature

<222> (5)..(5)

<223> Xaa can be any amino acid

<220>

<221> misc_feature

<222> (6)..(6)

<223> Xaa can be any amino acid

<220>

<221> misc_feature

<222> (1)..(2)

<223> Xaa at positions 1 and 2 must be present

<220>

<221> misc_feature

<222> (3)..(6)

<223> Xaa at positions 3 to 6 may be present

<220>

<221> misc_feature

<222> (7)..(7)

<223> Xaa can be Lys or Arg

<400> 2

Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5